These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 29808341)

  • 1. Conditional power as an aid in making interim decisions in observational studies.
    Walker AM
    Eur J Epidemiol; 2018 Sep; 33(9):777-784. PubMed ID: 29808341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data monitoring in clinical trials: the case for stochastic curtailment.
    Davis BR; Hardy RJ
    J Clin Epidemiol; 1994 Sep; 47(9):1033-42. PubMed ID: 7730906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A general formulation for a one-sided group sequential design.
    Moser BK; George SL
    Clin Trials; 2005; 2(6):519-28. PubMed ID: 16422312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new futility test approach in clinical interim data monitoring.
    Xue D
    Pharm Stat; 2012; 11(6):468-75. PubMed ID: 23015479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CP function: an alpha spending function based on conditional power.
    Jiang Z; Wang L; Li C; Xia J; Wang W
    Stat Med; 2014 Nov; 33(26):4501-14. PubMed ID: 25100033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reassessment of trial perspectives from interim data--a critical view.
    Bauer P; Koenig F
    Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous and group sequential conditional probability ratio tests for phase II clinical trials.
    Tan M; Xiong X
    Stat Med; 1996 Oct; 15(19):2037-51. PubMed ID: 8896138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical reasoning in clinical trials: hypothesis testing.
    Kelen GD; Brown CG; Ashton J
    Am J Emerg Med; 1988 Jan; 6(1):52-61. PubMed ID: 3275456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The perils with the misuse of predictive power.
    Dallow N; Fina P
    Pharm Stat; 2011; 10(4):311-7. PubMed ID: 20967762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating and utilizing probability of study success in clinical development.
    Wang Y; Fu H; Kulkarni P; Kaiser C
    Clin Trials; 2013; 10(3):407-13. PubMed ID: 23471634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p-value and power computations in multiple look trials.
    Peace KE; Schriver RC
    J Chronic Dis; 1987; 40(1):23-30. PubMed ID: 3805230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of methods for futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2005 Sep; 24(18):2747-64. PubMed ID: 16134130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of phase 2 interim analysis to expedite drug development decisions.
    Huang J; Das A; Burger HU; Zhong W; Zhang W; Lieberman G
    Contemp Clin Trials; 2014 Jul; 38(2):235-44. PubMed ID: 24854415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditional power calculations as an aid in the decision whether to continue a clinical trial.
    Andersen PK
    Control Clin Trials; 1987 Mar; 8(1):67-74. PubMed ID: 3568698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring clinical trials: conditional or predictive power?
    Spiegelhalter DJ; Freedman LS; Blackburn PR
    Control Clin Trials; 1986 Mar; 7(1):8-17. PubMed ID: 3956212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing.
    Tan M; Xiong X; Kutner MH
    Biometrics; 1998 Jun; 54(2):682-95. PubMed ID: 9629648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.